Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JANUARY 01, 2005 FBO #1132
SPECIAL NOTICE

A -- SH2 Domain-Binding Inhibitors Ready For Development

Notice Date
12/30/2004
 
Notice Type
Special Notice
 
NAICS
541710 — Research and Development in the Physical, Engineering, and Life Sciences
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
 
ZIP Code
21702
 
Solicitation Number
Reference-Number-SF-SH2-01
 
Description
The National Cancer Institute (NCI) seeks a Cooperative Research and Development Agreement (CRADA) collaborator to develop a novel class of macrocyclic Grb2 SH2 domain-binding inhibitors that disrupt the interactions between Grb2 SH2 domains of proteins and proteins with phosphorylated moieties. As typified by Compound 1 (see http://ttb.nci.nih.gov for structure), these compounds display enhanced binding affinity and are very potent against proliferating cells in cell-based assays. Potential Commercial Applications: Oncogenic and hyper-proliferative disorders such as cancer, inflammation, autoimmune disease and allergies Main Advantages of the Technology: In extracellular assays these macrocyclic peptide mimetics display enhanced Grb2 SH2 domain-binding affinity over previously described SH2 domain-binding inhibitors. Addition to the extracellular media of cell cultures without the use of carrier peptides or membrane permeabalization techniques, results in cellular blockade cytoplasmic association of Grb2 with cognate activated tyrosine kinases. Administration to cultures of cancer cells driven by Grb2-dependent growth factor receptor pathways results in antimitogenic effects at non-cytotoxic concentrations. Current State of Development: Biological evaluation is limited to extracellular assays and cell culture systems. Animal studies require preparation of larger quantities of inhibitor than are currently available. Synthetic complexity currently limits scale up of compound needed for animal studies. Further R&D Required: Improving the synthesis of these compounds Preparing larger quantities of inhibitor than are currently available Conducting in vivo animal studies to aid in determining clinical efficacy and drug development Patent Status: International Patent Application filed on 6/26/2003 Pertinent References: Wei CQ, et al. J Med Chem. 2003 Jan 16;46(2):244-54. Shi ZD, et al. J Med Chem. 2004 Apr 8;47(8):2166-9. Contact Information: CRADA Contact: Steven C. Fausch, Ph.D., Technology Transfer Branch, NCI Phone: 301-846-6820; E-mail: fauschs@mail.nih.gov Licensing Contact: George G. Pipia, Ph.D., Office of Technology Transfer, NIH Phone: 301-435-5560; E-mail: pipiag@mail.nih.gov
 
Record
SN00728083-W 20050101/041230211644 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.